Cooper C. Collins - 03 Nov 2025 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)

Reporting relationship: Director
Issuer ticker: TXMD
Reported as of: 03 Nov 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Nov 2025, 16:17:07 UTC
Prior SEC filing: 20 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Cooper C. Collins

Key filing fact

Cooper C. Collins filed Form 4 for TherapeuticsMD, Inc. (TXMD) on 05 Nov 2025.

Key facts

This page summarizes Cooper C. Collins's Form 4 filing for TherapeuticsMD, Inc. (TXMD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Nov 2025, 16:17.

Change

Previous filing in this sequence was filed on 20 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001485508 Primary reporting owner

Collins Cooper C.

Relationship: Director
Address: 951 YAMATO ROAD, SUITE 220, BOCA RATON
Signature: /s/ Cooper C. Collins
Signature date: 05 Nov 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TXMD transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +8,500
Change %
Price: $0.000000
Shares after: 8,500
Date: 03 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,500
Exercise price: $0.000000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028.